X |
Filing Date |
Trade Date |
Ticker |
Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2025-04-09 | ARWR | Anzalone Christopher Richard | CEO | S - Sale | $10.87 | -141,122 | 3,921,255 | -3% | -$1,533,337 | |||||
2025-03-13 | ARWR | Anzalone Christopher Richard | CEO | S - Sale | $15.07 | -51,425 | 4,062,377 | -1% | -$774,975 | ||||||
| DM | 2025-03-03 | ARWR | Anzalone Christopher Richard | CEO | S - Sale+OE | $17.58 | -300,000 | 3,773,802 | -7% | -$5,274,334 | |||||
2025-01-23 | ARWR | Olukotun Adeoye Y | Dir | S - Sale | $21.00 | -959 | 35,781 | -3% | -$20,139 | ||||||
2025-01-06 | ARWR | Hamilton James C | Chief Discovery, Trans Medicin | S - Sale | $19.82 | -32,729 | 272,122 | -11% | -$648,824 | ||||||
| M | 2025-01-06 | ARWR | O'Brien Patrick | COO, GC | S - Sale | $19.80 | -37,184 | 527,201 | -7% | -$736,059 | |||||
| M | 2025-01-06 | ARWR | Myszkowski Kenneth Allen | CFO | S - Sale | $19.77 | -45,167 | 455,433 | -9% | -$893,095 | |||||
2025-01-02 | ARWR | Anzalone Christopher Richard | CEO | S - Sale | $19.05 | -11,520 | 3,764,252 | 0% | -$219,456 | ||||||
2024-12-27 | ARWR | Olukotun Adeoye Y | Dir | S - Sale | $20.00 | -2,850 | 36,740 | -7% | -$57,000 | ||||||
2024-12-23 | ARWR | Anzalone Christopher Richard | CEO | S - Sale | $19.59 | -12,563 | 3,775,772 | 0% | -$246,109 | ||||||
2024-12-18 | ARWR | Anzalone Christopher Richard | CEO | S - Sale | $21.24 | -26,712 | 3,788,335 | -1% | -$567,486 | ||||||
| M | 2024-12-16 | ARWR | Waddill William D. | Dir | S - Sale | $21.97 | -7,495 | 40,378 | -16% | -$164,665 | |||||
| M | 2024-12-16 | ARWR | Given Douglas B | Dir | S - Sale | $21.91 | -5,547 | 124,167 | -4% | -$121,556 | |||||
2024-12-16 | ARWR | Vakiener Victoria | Dir | S - Sale | $21.91 | -8,994 | 21,211 | -30% | -$197,059 | ||||||
2024-07-02 | ARWR | Oliver Tracie | Chief Commercial Officer | S - Sale | $25.28 | -9,394 | 127,107 | -7% | -$237,480 | ||||||
2024-05-02 | ARWR | Vakiener Victoria | Dir | S - Sale | $23.31 | -1,799 | 30,205 | -6% | -$41,935 | ||||||
2024-04-01 | ARWR | Hamilton James C | Chief Discovery, Trans Medicin | S - Sale | $28.03 | -6,000 | 204,851 | -3% | -$168,180 | ||||||
| M | 2024-03-18 | ARWR | Lu Hongbo | Dir | P - Purchase | $27.66 | +3,000 | 33,680 | +10% | +$82,990 | |||||
2024-03-06 | ARWR | Myszkowski Kenneth Allen | CFO | S - Sale | $35.19 | -40,000 | 400,600 | -9% | -$1,407,600 | ||||||
| D | 2024-01-31 | ARWR | Anzalone Christopher Richard | CEO | S - Sale+OE | $32.35 | -57,499 | 3,715,048 | -2% | -$1,860,019 | |||||
2024-01-12 | ARWR | Hamilton James C | Chief Discovery, Trans Medicin | S - Sale | $36.89 | -7,940 | 210,851 | -4% | -$292,904 | ||||||
2024-01-11 | ARWR | Given Douglas B | Dir | S - Sale | $38.06 | -2,911 | 129,711 | -2% | -$110,788 | ||||||
2024-01-11 | ARWR | Waddill William D. | Dir | S - Sale | $38.07 | -3,934 | 47,870 | -8% | -$149,759 | ||||||
2024-01-11 | ARWR | Ferrari Mauro | Dir | S - Sale | $38.06 | -3,147 | 60,778 | -5% | -$119,787 | ||||||
2024-01-11 | ARWR | Vakiener Victoria | Dir | S - Sale | $38.10 | -4,720 | 32,001 | -13% | -$179,813 | ||||||
2024-01-05 | ARWR | Oliver Tracie | Chief Commercial Officer | S - Sale | $33.89 | -74 | 136,501 | 0% | -$2,508 | ||||||
2024-01-05 | ARWR | Myszkowski Kenneth Allen | CFO | S - Sale | $35.27 | -16,104 | 440,600 | -4% | -$567,910 | ||||||
2024-01-05 | ARWR | San Martin Javier | Chief Medical Officer | S - Sale | $35.26 | -8,303 | 198,497 | -4% | -$292,804 | ||||||
| M | 2024-01-03 | ARWR | Hamilton James C | Chief Discovery/Trans Medicine | S - Sale | $34.69 | -38,443 | 218,791 | -15% | -$1,333,529 | |||||
| M | 2024-01-03 | ARWR | O'Brien Patrick | COO, GC | S - Sale | $34.36 | -33,190 | 464,385 | -7% | -$1,140,362 | |||||
2024-01-02 | ARWR | Anzalone Christopher Richard | CEO | S - Sale | $31.01 | -9,952 | 3,715,048 | 0% | -$308,637 | ||||||
2023-12-20 | ARWR | Anzalone Christopher Richard | CEO | S - Sale | $28.54 | -12,000 | 3,725,000 | 0% | -$342,480 | ||||||
2023-11-20 | ARWR | San Martin Javier | Chief Medical Officer | S - Sale | $28.80 | -19,700 | 131,800 | -13% | -$567,315 | ||||||
2023-10-25 | ARWR | Anzalone Christopher Richard | CEO | S - Sale | $24.21 | -24,338 | 3,737,000 | -1% | -$589,223 | ||||||
2023-09-28 | ARWR | Vakiener Victoria | Dir | S - Sale | $26.33 | -1,550 | 21,734 | -7% | -$40,812 | ||||||
| D | 2023-09-18 | ARWR | Anzalone Christopher Richard | CEO | S - Sale+OE | $28.12 | -57,755 | 3,761,338 | -2% | -$1,624,223 | |||||
2023-07-03 | ARWR | Oliver Tracie | Chief Commercial Officer | S - Sale | $35.31 | -8,925 | 61,575 | -13% | -$315,142 | ||||||
2023-06-30 | ARWR | Hamilton James C | Chief Discovery/Trans Medicine | S - Sale | $35.53 | -3,000 | 188,484 | -2% | -$106,590 | ||||||
2023-06-27 | ARWR | Myszkowski Kenneth Allen | CFO | S - Sale | $36.20 | -15,000 | 381,704 | -4% | -$543,000 | ||||||
2023-05-05 | ARWR | Given Douglas B | Dir | S - Sale | $40.90 | -6,500 | 143,135 | -4% | -$265,850 | ||||||
| DM | 2023-05-03 | ARWR | Anzalone Christopher Richard | CEO | S - Sale+OE | $39.32 | -104,928 | 3,761,338 | -3% | -$4,125,674 | |||||
2023-03-03 | ARWR | Olukotun Adeoye Y | Dir | S - Sale | $32.65 | -11,350 | 7,867 | -59% | -$370,578 | ||||||
2023-02-27 | ARWR | Given Douglas B | Dir | S - Sale | $32.62 | -875 | 149,635 | -1% | -$28,543 | ||||||
| D | 2023-01-09 | ARWR | Waddill William D. | Dir | S - Sale+OE | $30.00 | -3,200 | 36,817 | -8% | -$96,000 | |||||
2023-01-05 | ARWR | O'Brien Patrick | COO, GC | S - Sale | $37.39 | -15,000 | 413,375 | -4% | -$560,850 | ||||||
2023-01-05 | ARWR | Hamilton James C | Chief Discovery/Trans Medicine | S - Sale | $37.40 | -13,803 | 191,484 | -7% | -$516,232 | ||||||
2023-01-03 | ARWR | O'Brien Patrick | COO, GC | S - Sale | $38.33 | -17,500 | 428,375 | -4% | -$670,802 | ||||||
2023-01-03 | ARWR | Hamilton James C | Chief Discovery/Trans Medicine | S - Sale | $38.38 | -10,338 | 205,287 | -5% | -$396,738 | ||||||
2022-12-29 | ARWR | Myszkowski Kenneth Allen | CFO | S - Sale | $40.00 | -30,625 | 336,704 | -8% | -$1,225,000 | ||||||
2022-11-21 | ARWR | San Martin Javier | Chief Medical Officer | S - Sale | $29.99 | -19,500 | 91,500 | -18% | -$584,738 | ||||||
| D | 2022-02-11 | ARWR | Anzalone Christopher Richard | CEO | S - Sale+OE | $51.91 | -146,388 | 4,057,634 | -3% | -$7,598,864 | |||||
2022-01-05 | ARWR | O'Brien Patrick | GC | S - Sale | $61.72 | -32,500 | 348,075 | -9% | -$2,005,875 | ||||||
2022-01-05 | ARWR | Myszkowski Kenneth Allen | CFO | S - Sale | $61.70 | -40,000 | 464,005 | -8% | -$2,467,941 | ||||||
| M | 2022-01-04 | ARWR | Hamilton James C | Senior Vice President | S - Sale | $64.57 | -25,625 | 155,625 | -14% | -$1,654,591 | |||||
2022-01-03 | ARWR | Waddill William D. | Dir | S - Sale | $64.72 | -4,500 | 25,750 | -15% | -$291,244 | ||||||
2022-01-03 | ARWR | Olukotun Adeoye Y | Dir | S - Sale | $64.75 | -4,050 | 4,950 | -45% | -$262,233 | ||||||
2022-01-03 | ARWR | De Backer Marianne | Dir | S - Sale | $64.71 | -4,500 | 17,000 | -21% | -$291,177 | ||||||
2022-01-03 | ARWR | Perry Michael S | Dir | S - Sale | $64.71 | -4,500 | 85,500 | -5% | -$291,192 | ||||||
2021-12-28 | ARWR | Given Douglas B | Dir | P - Purchase | $66.37 | +655 | 136,243 | 0% | +$43,472 | ||||||
2021-12-28 | ARWR | Ferrari Mauro | Dir | S - Sale | $66.82 | -3,400 | 36,571 | -9% | -$227,188 | ||||||
2021-12-15 | ARWR | Anzalone Christopher Richard | CEO | S - Sale | $67.56 | -60,000 | 3,219,022 | -2% | -$4,053,431 | ||||||
2021-11-19 | ARWR | San Martin Javier | Chief Medical Officer | S - Sale | $69.31 | -19,500 | 111,000 | -15% | -$1,351,589 | ||||||
| M | 2021-10-20 | ARWR | Anzalone Christopher Richard | CEO | S - Sale | $65.77 | -65,000 | 3,279,022 | -2% | -$4,274,982 | |||||
2021-09-13 | ARWR | Olukotun Adeoye Y | Dir | S - Sale | $63.76 | -5,000 | 9,000 | -36% | -$318,800 | ||||||
2021-09-09 | ARWR | Given Douglas B | Dir | S - Sale | $65.24 | -5,000 | 136,243 | -4% | -$326,200 | ||||||
2021-06-24 | ARWR | De Backer Marianne | Dir | S - Sale | $89.85 | -5,000 | 21,500 | -19% | -$449,250 | ||||||
2021-06-22 | ARWR | Hassard James | Chief Commercial Officer | S - Sale | $89.22 | -3,625 | 105,750 | -3% | -$323,423 | ||||||
2021-06-22 | ARWR | Given Douglas B | Dir | S - Sale | $89.21 | -4,500 | 141,243 | -3% | -$401,445 | ||||||
2021-02-22 | ARWR | Given Douglas B | Dir | S - Sale | $88.73 | -1,125 | 145,743 | -1% | -$99,821 | ||||||
| D | 2021-02-08 | ARWR | O'Brien Patrick | GC | S - Sale+OE | $88.46 | -90,000 | 293,375 | -23% | -$7,961,240 | |||||
2021-01-15 | ARWR | Given Douglas B | Dir | S - Sale | $83.28 | -3,000 | 146,868 | -2% | -$249,840 | ||||||
2021-01-14 | ARWR | Hamilton James C | Senior Vice President | S - Sale | $81.29 | -10,000 | 126,250 | -7% | -$812,942 | ||||||
| M | 2021-01-11 | ARWR | Myszkowski Kenneth Allen | CFO | S - Sale | $81.02 | -13,038 | 444,005 | -3% | -$1,056,310 | |||||
2021-01-07 | ARWR | Hassard James | Chief Commercial Officer | S - Sale | $75.00 | -15,625 | 109,375 | -13% | -$1,171,875 | ||||||
2021-01-06 | ARWR | O'Brien Patrick | GC | S - Sale | $72.41 | -25,000 | 293,375 | -8% | -$1,810,346 | ||||||
2021-01-06 | ARWR | Myszkowski Kenneth Allen | CFO | S - Sale | $72.44 | -30,625 | 457,043 | -6% | -$2,218,477 | ||||||
| M | 2021-01-05 | ARWR | Hamilton James C | Senior Vice President | S - Sale | $72.51 | -38,750 | 136,250 | -22% | -$2,809,578 | |||||
2021-01-04 | ARWR | Perry Michael S | Dir | S - Sale | $76.09 | -4,000 | 184,000 | -2% | -$304,360 | ||||||
2021-01-04 | ARWR | Given Douglas B | Dir | S - Sale | $76.08 | -4,000 | 119,368 | -3% | -$304,320 | ||||||
2021-01-04 | ARWR | Waddill William D. | Dir | S - Sale | $76.08 | -3,750 | 30,250 | -11% | -$285,300 | ||||||
2020-12-17 | ARWR | Given Douglas B | Dir | S - Sale | $79.32 | -9,575 | 129,738 | -7% | -$759,443 | ||||||
2020-12-10 | ARWR | Waddill William D. | Dir | S - Sale | $71.26 | -3,000 | 25,000 | -11% | -$213,780 | ||||||
| DM | 2020-12-08 | ARWR | Anzalone Christopher Richard | CEO | S - Sale+OE | $68.73 | -55,000 | 2,505,237 | -2% | -$3,780,347 | |||||
| M | 2020-11-19 | ARWR | Bradshaw Curt | Chief Scientific Officer | S - Sale | $69.06 | -31,250 | 0 | -100% | -$2,158,125 | |||||
2020-11-19 | ARWR | San Martin Javier | Chief Medical Officer | S - Sale | $69.39 | -19,500 | 130,500 | -13% | -$1,353,105 | ||||||
| D | 2020-11-09 | ARWR | Myszkowski Kenneth Allen | CFO | S - Sale+OE | $69.37 | -43,505 | 427,668 | -9% | -$3,018,071 | |||||
2020-10-08 | ARWR | De Backer Marianne | Dir | P - Purchase | $50.47 | +1,000 | 17,500 | +6% | +$50,465 | ||||||
2020-10-23 | ARWR | Anzalone Christopher Richard | CEO | S - Sale | $58.21 | -100,000 | 2,505,237 | -4% | -$5,821,032 | ||||||
| D | 2020-10-20 | ARWR | Myszkowski Kenneth Allen | CFO | S - Sale+OE | $54.04 | -29,166 | 427,668 | -6% | -$1,576,131 | |||||
2020-10-09 | ARWR | Ferrari Mauro | Dir | S - Sale | $48.00 | -10,000 | 30,971 | -24% | -$480,000 | ||||||
| D | 2020-08-13 | ARWR | Anzalone Christopher Richard | CEO | S - Sale+OE | $41.35 | -50,000 | 2,605,237 | -2% | -$2,067,500 | |||||
2020-06-25 | ARWR | Anzalone Christopher Richard | CEO | S - Sale | $38.81 | -100,000 | 2,605,237 | -4% | -$3,881,017 | ||||||
| M | 2020-01-13 | ARWR | De Backer Marianne | Dir | P - Purchase | $33.56 | +4,000 | 16,500 | +32% | +$134,240 | |||||
2020-05-12 | ARWR | Perry Michael S | Dir | S - Sale | $35.83 | -36,000 | 8,000 | -82% | -$1,289,891 | ||||||
2020-05-11 | ARWR | Waddill William D. | Dir | S - Sale | $36.54 | -26,000 | 28,000 | -48% | -$950,040 | ||||||
| DM | 2020-04-27 | ARWR | Given Bruce D | COO | S - Sale+OE | $40.00 | -5,401 | 850,730 | -1% | -$216,040 | |||||
| D | 2020-04-20 | ARWR | Given Bruce D | COO | S - Sale+OE | $40.00 | -23,515 | 851,734 | -3% | -$940,600 | |||||
2020-04-14 | ARWR | Given Douglas B | Dir | S - Sale | $36.89 | -25,000 | 154,813 | -14% | -$922,250 | ||||||
| D | 2020-01-21 | ARWR | Myszkowski Kenneth Allen | CFO | S - Sale+OE | $49.44 | -40,313 | 384,223 | -9% | -$1,992,925 | |||||
2020-01-06 | ARWR | Given Bruce D | COO | S - Sale | $60.13 | -35,613 | 858,993 | -4% | -$2,141,285 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |